​

Protagonist Therapeutics (PTGX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Protagonist Therapeutics Revenue Highlights

0

Latest Revenue (Q)

$4.67M

Main Segment (Y)

Development Services

Main Geography (Y)

License and Collaboration Agreement

Protagonist Therapeutics Revenue by Period

Protagonist Therapeutics Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$60.00M125.73%
2022-12-31$26.58M-2.84%
2021-12-31$27.36M-4.44%
2020-12-31$28.63M12293.07%
2019-12-31$231.00K-99.25%
2018-12-31$30.93M54.14%
2017-12-31$20.06M100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31--

Protagonist Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Protagonist Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$4.67M12.19%
2024-06-30$4.17M-98.37%
2024-03-31$254.95M324.92%
2023-12-31$60.00M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30--100.00%
2022-06-30$859.00K-96.66%
2022-03-31$25.72M198.50%
2021-12-31$8.62M-16.23%
2021-09-30$10.29M354.13%
2021-06-30$2.27M-63.40%
2021-03-31$6.19M9.54%
2020-12-31$5.65M-56.92%
2020-09-30$13.11M110.94%
2020-06-30$6.22M70.47%
2020-03-31$3.65M34.13%
2019-12-31$2.72M-34.34%
2019-09-30$4.14M-150.57%
2019-06-30$-8.19M-624.94%
2019-03-31$1.56M-33.70%
2018-12-31$2.35M-61.53%
2018-09-30$6.12M-47.60%
2018-06-30$11.67M8.28%
2018-03-31$10.78M-4.44%
2017-12-31$11.28M28.48%
2017-09-30$8.78M100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31--

Protagonist Therapeutics generated $4.67M in revenue during Q3 2024, up 12.19% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Protagonist Therapeutics Revenue Breakdown

Protagonist Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 21Dec 20Dec 19
Development Services$15.30M---
License and Collaboration Agreement-$18.60M--
Financial Service Other--$1.50M-
License And Collaborative Revenue--$28.60M$200.00K

Protagonist Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Development Services (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Mar 19Sep 18Jun 18Mar 18
Development Services$4.70M$9.70M$900.00K--------------
License and Collaboration Agreement---$900.00K$25.70M$10.60M-----------
License And Service------$8.00M----------
License And Collaborative Revenue-------$95.80M$96.30M$6.60M$99.40M$113.90M$113.60M$1.60M$6.10M$11.67M$10.78M
Financial Service Other-------$200.00K$600.00K$500.00K$500.00K$500.00K-----

Protagonist Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Development Services (100.00%).

Protagonist Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21Dec 20Dec 19
License and Collaboration Agreement$18.60M--
Financial Service Other-$1.50M-
License And Collaborative Revenue-$28.60M$200.00K

Protagonist Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: License and Collaboration Agreement (100.00%).

Quarterly Revenue by Country

CountryJun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Mar 19Sep 18Jun 18Mar 18
License and Collaboration Agreement$900.00K$25.70M$10.60M-----------
License And Service---$8.00M----------
License And Collaborative Revenue----$95.80M$96.30M$6.60M$99.40M$113.90M$113.60M$1.60M$6.10M$11.67M$10.78M
Financial Service Other----$200.00K$600.00K$500.00K$500.00K$500.00K-----

Protagonist Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 22: License and Collaboration Agreement (100.00%).

Protagonist Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$263.40M$102.40M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
KURAKura Oncology$53.88M-
VRNAVerona Pharma$42.28M$5.62M
STOKStoke Therapeutics$36.55M$4.89M
MRUSMerus$36.13M$11.77M
SNDXSyndax Pharmaceuticals$23.68M$12.50M
RNAAvidity Biosciences$10.90M$2.04M
RLAYRelay Therapeutics$10.01M-
IDYAIDEAYA Biosciences$7.00M-
XFORX4 Pharmaceuticals$2.56M$560.00K
AKROAkero Therapeutics--
BDTXBlack Diamond Therapeutics--
PTGXProtagonist Therapeutics-$4.67M
VTYXVentyx Biosciences--
RVMDRevolution Medicines--
REPLReplimune Group--
ABOSAcumen Pharmaceuticals--
TERNTerns Pharmaceuticals--
HOOKHOOKIPA Pharma-$4.70M
PLRXPliant Therapeutics--

PTGX Revenue FAQ

What is Protagonist Therapeutics’s yearly revenue?

Protagonist Therapeutics's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $60M, representing an increase of 125.73% compared to 2022. PTGX's yearly revenue for 2022 was $26.58M, representing a decrease of -2.84% compared to 2021.

What is Protagonist Therapeutics’s quarterly revenue?

Protagonist Therapeutics's quarterly revenue for Q3 2024 was $4.68M, a 12.19% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $4.17M, a -98.37% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). PTGX's quarterly revenue for Q1 2024 was $254.95M, a 324.92% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Protagonist Therapeutics’s revenue growth rate?

Protagonist Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Protagonist Therapeutics’s revenue streams?

Protagonist Therapeutics's revenue streams in c 24 are Development Services

What is Protagonist Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Protagonist Therapeutics was Development Services. This segment made a revenue of $15.3M, representing 100.00% of the company's total revenue.